FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1155-1157 March 17, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Simons, F. E. R. PubMed Citation

To the Editor: Simons (Nov. 18 issue)¹ provides a comprehensive review of the advances in drug therapy with histamine H₁-receptor antagonists. However, the author states that there is no current evidence supporting the use of such therapy for asthma — a statement possibly biased by selective referencing. There are recent data in the literature that suggest that modern H₁-receptor antagonists such as desloratadine, fexofenadine, and levocetirizine have antiinflammatory effects in patients with atopic asthma.^2,3,4 Indeed, fexofenadine improves airway hyperresponsiveness and reduces exhaled nitric oxide, improves peak expiratory flow, and reduces albuterol use, to a degree similar to that . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.